nafamostat has been researched along with Envenomation, Snakebite in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albulescu, LO | 1 |
| Xie, C | 1 |
| Ainsworth, S | 1 |
| Alsolaiss, J | 1 |
| Crittenden, E | 1 |
| Dawson, CA | 1 |
| Softley, R | 1 |
| Bartlett, KE | 1 |
| Harrison, RA | 1 |
| Kool, J | 1 |
| Casewell, NR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of a Multi-Dose Regimen of Oral Varespladib-Methyl in Subjects Bitten by Venomous Snakes[NCT04996264] | Phase 2 | 96 participants (Actual) | Interventional | 2021-08-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for nafamostat and Envenomation, Snakebite
| Article | Year |
|---|---|
A therapeutic combination of two small molecule toxin inhibitors provides broad preclinical efficacy against viper snakebite.
Topics: Animals; Antivenins; Asia; Benzamidines; Central America; Dimercaprol; Disease Models, Animal; Drug | 2020 |